ArticleJournal of neuro-oncology2026
Timing of adjuvant chemoradiotherapy after resection and survival in glioblastoma: a single-centre cohort analysis.
Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeCurrent guidelines recommend initiating adjuvant chemoradiotherapy within six weeks after glioblastoma surgery, yet delays are common and their impact on survival remains debated. This study evaluates the effect of chemoradiotherapy timing in a monocentric retrospective cohort, with a median radiotherapy (RT) initiation time longer than recommended delays, offering new insight into this underexplored factor.
methodsTwo hundred and fifty-four (254) consecutive patients with newly diagnosed glioblastoma treated by surgical resection followed by chemoradiotherapy between January 2015 and August 2023 were retrospectively included. Patients were classified as 'early' (< 42 days) or 'late' (≥ 42 days) based on the interval from surgery to chemoradiotherapy initiation.
resultsMedian time to radiotherapy initiation was 51 days, and 76% of the cohort started chemoradiotherapy ≥ 42 days after surgery. Chemoradiotherapy initiation before versus after 42 days was not associated with overall survival (501 vs. 518 days; 16.4 vs. 17.0 months; HR 1.11, 95% CI 0.80-1.53; p = 0.542) or progression-free survival (HR 1.06, 95% CI 0.77-1.45; p = 0.726), either in univariable or multivariable analyses, including the model incorporating MGMT promoter status. In contrast, maximal extent of resection and MGMT promoter methylation were independently associated with improved survival.
conclusionIn our cohort of newly diagnosed glioblastoma patients who underwent surgical resection, initiating adjuvant chemoradiotherapy more than six weeks after surgery was not associated with worse overall survival or progression-free survival.
Indexed as
Identifiers
42141297What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.